Catheter Precision, Inc. Announces Initial LockeT Purchase From the University of Tennessee Medical Center
Catheter Precision (NYSE American:VTAK) has received its first purchase order for LockeT from the southeast region, specifically from The University of Tennessee Medical Center in Knoxville. This development marks the beginning of 2025 and follows the company's recent expansion of its US sales and clinical team for LockeT's national product launch.
The University of Tennessee Medical Center, a 710-bed facility, serves as the region's academic medical center, Magnet® recognized hospital, and Level I Trauma Center. It functions as a major referral center for East Tennessee, Southeast Kentucky, and Western North Carolina, and houses the region's only dedicated Heart Hospital.
Catheter Precision (NYSE American:VTAK) ha ricevuto il suo primo ordine d'acquisto per LockeT dalla regione sud-est, specificamente dalla University of Tennessee Medical Center di Knoxville. Questo sviluppo segna l'inizio del 2025 e segue l'espansione recente del team vendite e clinico negli Stati Uniti della compagnia per il lancio nazionale del prodotto LockeT.
La University of Tennessee Medical Center, una struttura con 710 letti, funge da centro medico accademico della regione, ospedale riconosciuto Magnet® e Centro Traumatologico di Livello I. Essa opera come un importante centro di riferimento per l'est del Tennessee, il sud-est del Kentucky e il western North Carolina, e ospita l'unico Ospedale Cardiaco dedicato della regione.
Catheter Precision (NYSE American:VTAK) ha recibido su primer pedido de compra para LockeT de la región sureste, específicamente de The University of Tennessee Medical Center en Knoxville. Este desarrollo marca el inicio de 2025 y sigue la reciente expansión del equipo de ventas y clínico en EE. UU. de la empresa para el lanzamiento nacional del producto LockeT.
The University of Tennessee Medical Center, una instalación de 710 camas, sirve como el centro médico académico de la región, un hospital reconocido como Magnet® y un Centro de Trauma de Nivel I. Funciona como un importante centro de referencia para el este de Tennessee, el sureste de Kentucky y el oeste de Carolina del Norte, y alberga el único hospital cardiaco dedicado de la región.
Catheter Precision (NYSE American:VTAK)는 남동부 지역, 특히 테네시 대학교 의학 센터로부터 LockeT에 대한 첫 번째 구매 주문을 받았습니다. 이 발전은 2025년의 시작을 의미하며, LockeT의 국가 제품 출시를 위한 미국의 판매 및 임상 팀의 최근 확장을 따릅니다.
테네시 대학교 의학 센터는 710개 침대를 갖춘 시설로, 이 지역의 학술 의료 센터이자 Magnet® 인증 병원, 1급 외상 센터로 기능하고 있습니다. 동부 테네시, 남동부 켄터키, 서부 노스캐롤라이나의 주요 의뢰 센터로 작용하며, 이 지역 유일의 전담 심장병원이 있습니다.
Catheter Precision (NYSE American:VTAK) a reçu sa première commande d'achat pour LockeT de la région sud-est, en particulier de The University of Tennessee Medical Center à Knoxville. Ce développement marque le début de 2025 et fait suite à l'expansion récente de l'équipe de vente et clinique de l'entreprise aux États-Unis pour le lancement national du produit LockeT.
The University of Tennessee Medical Center, un établissement de 710 lits, sert de centre médical académique de la région, d'hôpital reconnu Magnet® et de Centre de Traumatologie de Niveau I. Il fonctionne comme un important centre de référence pour l'est du Tennessee, le sud-est du Kentucky et l'ouest de la Caroline du Nord, et abrite le seul hôpital cardiaque dédié de la région.
Catheter Precision (NYSE American:VTAK) hat seinen ersten Einkaufsauftrag für LockeT aus der Südostregion erhalten, und zwar von The University of Tennessee Medical Center in Knoxville. Diese Entwicklung markiert den Beginn des Jahres 2025 und folgt der jüngsten Expansion des Verkaufs- und klinischen Teams des Unternehmens in den USA für den nationalen Produkteinführungsstart von LockeT.
Die University of Tennessee Medical Center, eine Einrichtung mit 710 Betten, fungiert als akademisches medizinisches Zentrum der Region, als Magnet® anerkanntes Krankenhaus und als Trauma-Zentrum der Stufe I. Sie agiert als wichtiges Überweisungszentrum für Ost-Tennessee, Südost-Kentucky und West-North-Carolina und beherbergt das einzige spezialisierte Herzkrankenhaus der Region.
- Secured first LockeT purchase order from a major academic medical center
- Successfully expanding into new territories following sales strategy implementation
- None.
Insights
The initial LockeT purchase order from the University of Tennessee Medical Center represents a strategic market entry into the southeast region for Catheter Precision. The 710-bed facility's status as a Level I Trauma Center and regional referral hub positions it as a key reference account that could influence adoption across the broader southeastern healthcare network.
A prestigious first customer in a new territory typically serves as a bellwether for regional market penetration. The timing of this order, coming after the company's sales force expansion, validates their commercial strategy and suggests potential for accelerated revenue growth. However, without disclosed order value or pricing details, the immediate financial impact remains uncertain.
For a micro-cap company with a
The University of Tennessee Medical Center's adoption of LockeT carries strategic significance beyond the immediate sale. As the region's only dedicated Heart Hospital, their procedural volumes and influence on clinical practices make them an ideal launch partner. Their Magnet® recognition, awarded to only
The southeastern U.S. represents a substantial market opportunity, characterized by higher cardiovascular disease prevalence compared to national averages. Success in this region could create a domino effect, particularly given the facility's role in training future clinicians who may influence procurement decisions at other institutions throughout their careers.
FORT MILL, SC / ACCESSWIRE / January 13, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the southeast region.
As previously announced, the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.
This purchase order comes from The University of Tennessee Medical Center in Knoxville, Tennessee. As the region's academic medical center, Magnet® recognized hospital and Level I Trauma Center, The University of Tennessee Medical Center serves as a major referral center for East Tennessee, Southeast Kentucky and Western North Carolina. The 710-bed hospital also is home of the region's only dedicated Heart Hospital.
Marie-Claude Jacques, Chief Commercial Officer, said "We are excited to start 2025 with a purchase order from a new facility, especially one as prestigious as the University of Tennessee Medical Center. We continue to see growth and usage in new territories throughout the US further indicating successful implementation of our sales strategy."
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
About LockeT
Catheter Precision's LockeT is a suture retention device intended to assist in hemostasis after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
Additional Information
This release and all other releases from Catheter Precision, Inc. are limited in their entirety by other information filed with the SEC including, but not limited to, our latest 10-K, 10-Q's, and 8-K's, and should be read in conjunction with those filings.
Forward Looking Statements
Statements in this press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as "believe," "anticipate," "may," "might," "can," "could," "continue," "depends," "expect," "expand," "forecast," "intend," "predict," "plan," "rely," "should," "will," "may," "seek," or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring. The Company's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
IR@catheterprecision.com
# # #
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision, Inc.
View the original press release on accesswire.com
FAQ
What is the significance of VTAK's first LockeT purchase order from University of Tennessee Medical Center?
When did VTAK receive its first LockeT purchase order from the southeast region?
Which healthcare facility placed the first LockeT order in the southeast region for VTAK?
How does this LockeT purchase align with VTAK's expansion strategy?
